All In Biotech

Drug Trial Radar · NCT05522439

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Pharmacodynamic, Efficacy and Safety of Multiple Subcutaneous Injections of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Dec 22, 2022

Primary completion

Sep 12, 2024

Study completion Sep 12, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.

Conditions

  • Asthma With Eosinophilic Phenotype

Interventions

  • SHR-1703Drug

    SHR-1703 will be administered by SC injection.

  • SHR-1703 PlaceboDrug

    Matching Placebo will be administered by the SC route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from baseline in Blood EosinophilsTime frame: Up to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.